-$0.23 EPS Expected for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) This Quarter

Share on StockTwits

Wall Street brokerages expect AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to post earnings per share of ($0.23) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for AcelRx Pharmaceuticals’ earnings, with estimates ranging from ($0.25) to ($0.21). AcelRx Pharmaceuticals reported earnings of ($0.20) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 15%. The company is scheduled to announce its next quarterly earnings report on Thursday, August 1st.

According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full-year earnings of ($0.84) per share for the current fiscal year, with EPS estimates ranging from ($0.93) to ($0.79). For the next year, analysts forecast that the business will report earnings of ($0.67) per share, with EPS estimates ranging from ($0.84) to ($0.47). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.06. The business had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.85 million.

A number of equities analysts recently issued reports on ACRX shares. Credit Suisse Group started coverage on shares of LTC Properties in a research report on Wednesday, July 10th. They set an “underperform” rating and a $19.00 price objective for the company. B. Riley reiterated a “buy” rating on shares of Champion Iron in a research report on Wednesday, April 24th. Zacks Investment Research upgraded shares of DLH from a “sell” rating to a “hold” rating in a research report on Tuesday, July 9th. ValuEngine raised shares of VESTAS WIND SYS/ADR from a “hold” rating to a “buy” rating in a research note on Thursday, May 9th. Finally, LADENBURG THALM/SH SH reaffirmed a “buy” rating on shares of Paratek Pharmaceuticals in a research note on Thursday, May 9th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $7.47.

A number of institutional investors have recently made changes to their positions in ACRX. BlackRock Inc. boosted its holdings in AcelRx Pharmaceuticals by 196.6% in the fourth quarter. BlackRock Inc. now owns 2,331,736 shares of the specialty pharmaceutical company’s stock worth $5,386,000 after acquiring an additional 1,545,702 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of AcelRx Pharmaceuticals by 55.1% during the fourth quarter. Bank of New York Mellon Corp now owns 67,149 shares of the specialty pharmaceutical company’s stock worth $155,000 after purchasing an additional 23,866 shares during the period. Raymond James & Associates lifted its holdings in shares of AcelRx Pharmaceuticals by 96.7% during the fourth quarter. Raymond James & Associates now owns 29,500 shares of the specialty pharmaceutical company’s stock worth $68,000 after purchasing an additional 14,500 shares during the period. Northern Trust Corp lifted its holdings in shares of AcelRx Pharmaceuticals by 15.4% during the fourth quarter. Northern Trust Corp now owns 132,197 shares of the specialty pharmaceutical company’s stock worth $305,000 after purchasing an additional 17,672 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of AcelRx Pharmaceuticals by 38.2% during the fourth quarter. Geode Capital Management LLC now owns 478,349 shares of the specialty pharmaceutical company’s stock worth $1,104,000 after purchasing an additional 132,252 shares during the period. Institutional investors own 15.52% of the company’s stock.

Shares of NASDAQ:ACRX traded down $0.06 during midday trading on Thursday, hitting $2.78. The stock had a trading volume of 70,895 shares, compared to its average volume of 1,728,354. The stock has a 50-day moving average price of $2.46. The company has a market capitalization of $224.89 million, a P/E ratio of -3.42 and a beta of 2.24. The company has a quick ratio of 4.91, a current ratio of 5.03 and a debt-to-equity ratio of 0.79. AcelRx Pharmaceuticals has a fifty-two week low of $1.99 and a fifty-two week high of $5.05.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Featured Article: Why do companies issue convertible shares?

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Establishment Labs Holdings Inc Expected to Earn FY2023 Earnings of $0.28 Per Share
Establishment Labs Holdings Inc Expected to Earn FY2023 Earnings of $0.28 Per Share
Research Analysts Set Expectations for Brixmor Property Group Inc’s FY2021 Earnings
Research Analysts Set Expectations for Brixmor Property Group Inc’s FY2021 Earnings
Jefferies Financial Group Comments on GCP Applied Technologies Inc’s FY2021 Earnings
Jefferies Financial Group Comments on GCP Applied Technologies Inc’s FY2021 Earnings
Amgen, Inc.  Expected to Post FY2022 Earnings of $17.05 Per Share
Amgen, Inc. Expected to Post FY2022 Earnings of $17.05 Per Share
Kala Pharmaceuticals Inc to Post FY2022 Earnings of $3.66 Per Share, Wedbush Forecasts
Kala Pharmaceuticals Inc to Post FY2022 Earnings of $3.66 Per Share, Wedbush Forecasts
Dillard’s, Inc. to Post FY2021 Earnings of $4.64 Per Share, Wedbush Forecasts
Dillard’s, Inc. to Post FY2021 Earnings of $4.64 Per Share, Wedbush Forecasts


© 2006-2019 Ticker Report